A Multiparametric MRI-based Radiomics Model for Stratifying Postoperative Recurrence in Luminal B Breast Cancer
-
Published:2024-02-29
Issue:4
Volume:37
Page:1475-1487
-
ISSN:2948-2933
-
Container-title:Journal of Imaging Informatics in Medicine
-
language:en
-
Short-container-title:J Digit Imaging. Inform. med.
Author:
Xu Kepei,Hua Meiqi,Mai Ting,Ren Xiaojing,Fang Xiaozheng,Wang Chunjie,Ge Min,Qian Hua,Xu Maosheng,Zhang Ruixin
Abstract
Abstract
This study aims to develop an MRI-based radiomics model to assess the likelihood of recurrence in luminal B breast cancer. The study analyzed medical images and clinical data from 244 patients with luminal B breast cancer. Of 244 patients, 35 had experienced recurrence and 209 had not. The patients were randomly divided into the training set (51.5 ± 12.5 years old; n = 171) and the test set (51.7 ± 11.3 years old; n = 73) in a ratio of 7:3. The study employed univariate and multivariate Cox regression along with the least absolute shrinkage and selection operator (LASSO) regression methods to select radiomics features and calculate a risk score. A combined model was constructed by integrating the risk score with the clinical and pathological characteristics. The study identified two radiomics features (GLSZM and GLRLM) from DCE-MRI that were used to calculate a risk score. The AUCs were 0.860 and 0.868 in the training set and 0.816 and 0.714 in the testing set for 3- and 5-year recurrence risk, respectively. The combined model incorporating the risk score, pN, and endocrine therapy showed improved predictive power, with AUCs of 0.857 and 0.912 in the training set and 0.943 and 0.945 in the testing set for 3- and 5-year recurrence risk, respectively. The calibration curve of the combined model showed good consistency between predicted and measured values. Our study developed an MRI-based radiomics model that integrates clinical and radiomics features to assess the likelihood of recurrence in luminal B breast cancer. The model shows promise for improving clinical risk stratification and treatment decision-making.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249, 2021 2. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A: Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26(4):444–457, 2017 3. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A: Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol 34(9):927–935, 2016 4. Bago-Horvath Z, Rudas M, Singer CF, Greil R, Balic M, Lax SF, Kwasny W, Hulla W, Gnant M, Filipits M: Predictive value of molecular subtypes in premenopausal women with hormone receptor-positive early breast cancer: results from the ABCSG Trial 5. Clin Cancer Res 26(21):5682–5688, 2020 5. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E: Early breast cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol 30(10):1674, 2019
|
|